Accretion Pharmaceuticals share news, announcements and annual reports
NSE: ACCPLPharmaceuticals & Biotechnology
Share price at the NSE close on 28 Oct 2026. Previous close ₹185.00.
28 Oct: open ₹181.95, high ₹185.00, low ₹181.95
- Next results date: the board meets on 31 Oct 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. Market capitalisation: how it is worked out
- ₹206 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 21.27
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 3.76
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 27.6%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.23
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 4,800100.0% delivered
Accretion Pharmaceuticals has 54 announcements on record, routine notices left out; 5 in the 30 days to 28 Oct 2026, the latest on 24 Oct 2026.
Next board meeting and results date
As the company gave notice to the exchange.Accretion Pharmaceuticals half-yearly results
The board meets on 31 Oct 2026 to consider financial results
Notice filed 24 Oct 2026
To consider and approve the financial results for the period ended September 30, 2026
Accretion Pharmaceuticals annual reports, presentations and earnings calls
The company's own documents, latest first.Accretion Pharmaceuticals financials, year by year
Annual reports2
- Annual report, year to Mar 20263 Aug 2026
- Annual report, year to Mar 20253 Sep 2025
Investor presentations2
- Investor Presentation15 May 2026
- Investor Presentation17 Nov 2025
Earnings calls2
- Transcript22 Nov 2025
- Link of Recording18 Nov 2025
Accretion Pharmaceuticals share news and announcements
Newest first. Page 1 of 2.
Oct 2026
24 Oct · Board meeting
10 Oct · Amendment to AOA/MOA
10 Oct · Meeting
10 Oct · Meeting
Sep 2026
9 Sep · Meeting
1 Sep · Amendment to AOA/MOA
Aug 2026
27 Aug · Meeting
5 Aug · General Updates
Jul 2026
6 Jul · Management
Jun 2026
23 Jun · Analysts
May 2026
8 May · Management
8 May · Results
Apr 2026
Mar 2026
10 Mar · Analysts
3 Mar · Analysts
Jan 2026
7 Jan · Legal
Dec 2025
8 Dec · Analysts
Nov 2025
27 Nov
26 Nov · Analysts
26 Nov · Analysts
24 Nov · Analysts
14 Nov · Results
13 Nov · Analysts
Oct 2025
28 Oct
Sep 2025
25 Sep · Meeting
19 Sep · General Updates
15 Sep · Analysts
3 Sep · Meeting
1 Sep · Board meeting
Jul 2025
Jun 2025
11 Jun · Results
10 Jun · Board meeting
How the price met the news
The first session after each announcement, beside the market.
That dayThe first session's move. The first session's close after the announcement against the close before it, as a per cent change, on prices adjusted for splits and bonuses.Against the Nifty 500Against the Nifty 500. The share's move less the Nifty 500's move the same session, in percentage points (pts).Market median on that newsThe market's median move on that news. The middle first-session move of every listed company that filed the same kind of announcement, half moving more and half less.Five sessionsFive sessions' move. The close five sessions after the announcement against the close before it, as a per cent change.Five sessions against the Nifty 500Five sessions against the Nifty 500. The share's five-session move less the Nifty 500's move over the same five sessions, in percentage points (pts).Volume, times usualVolume, times usual. The session's shares traded divided by the average of the twenty sessions before it.
- 6 Jul 2026Board or managers changedup 2.15%+1.6 pts vs Nifty 500market median 0.0% · five sessions +0.9% (+0.7 pts vs Nifty 500) · volume 0.1× usual · The announcement
- 3 Jul 2026Board or managers changeddown 3.92%−4.1 pts vs Nifty 500market median 0.0% · five sessions −0.7% (0.0 pts vs Nifty 500) · volume 0.3× usual · The announcement
- 11 May 2026Resultsup 4.16%+5.5 pts vs Nifty 500market median −0.7% · five sessions +1.5% (+4.1 pts vs Nifty 500) · volume 2.8× usual · The announcement
- 17 Nov 2025Resultsdown 5.47%−6.0 pts vs Nifty 500market median −0.7% · five sessions +18.5% (+18.7 pts vs Nifty 500) · volume 2.2× usual · The announcement
- 11 Jun 2025Resultsup 13.61%+13.6 pts vs Nifty 500market median −0.7% · five sessions +10.3% (+11.9 pts vs Nifty 500) · The announcement
- 6 Jun 2025Board or managers changedup 2.03%+1.0 pts vs Nifty 500market median 0.0% · five sessions +21.6% (+21.1 pts vs Nifty 500) · The announcement
- 27 May 2025Board or managers changeddown 4.99%−4.6 pts vs Nifty 500market median 0.0% · five sessions −5.8% (−5.4 pts vs Nifty 500) · The announcement
Accretion Pharmaceuticals results filing dates and deadlines
Listed companies must file half-yearly results within 45 days, and the year's within 60.
Days to fileDays to file. The days from the period's end to the day the results reached the exchange.DeadlineDeadline, days. The days the rules allow from the period's end: 45 for a quarter or half year, and 60 for the year and the March quarter filed with it. A company that listed after the period ended has until 21 days after its listing where that is later.